Retinopathy Of Prematurity

Disclaimer: This document is intended as a comprehensive clinical reference for healthcare professionals, modeled after resources like UpToDate. It provides evidence-based medical information for educational purposes and to support clinical decision-making. However, it is not a substitute for professional medical advice, diagnosis, or treatment. Clinical practice must always be guided by the clinician's judgment, the individual patient's circumstances, and the most current local guidelines and evidence. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to patient care. Drug dosages and treatment protocols may vary and should be verified with official prescribing information and current guidelines.

Overview

• Definition: Retinopathy of Prematurity (ROP) is a vasoproliferative disorder affecting the developing retinal vasculature of premature infants, characterized by abnormal blood vessel growth in the retina. It typically affects infants born before 31 weeks of gestation and/or weighing less than 1500 grams, but can occur in larger, more mature infants with severe systemic illness.
• Epidemiology:
  • Incidence: ROP affects approximately 50-70% of infants born at <1250g or <30 weeks gestational age. Severe ROP requiring treatment (Type 1 ROP) occurs in about 5-10% of these infants.
  • Global Burden: While initially a disease of developed countries, improved neonatal care in middle-income countries has led to an increase in ROP cases, as more extremely premature infants survive.
  • Demographics: Primarily affects infants of very low birth weight (VLBW, <1500g) and very low gestational age (VLGA, <32 weeks). The risk is inversely proportional to birth weight and gestational age.
• Classification: ROP is classified according to the International Classification of Retinopathy of Prematurity (ICROP), which defines the disease by:
  1. Location (Zones):
     • Zone I: Innermost circle centered on the optic disc, extending to twice the distance from the optic disc to the fovea (approx. 30 degrees).
     • Zone II: Extends concentrically from the edge of Zone I to the nasal ora serrata and to an equivalent distance temporally.
     • Zone III: A crescent-shaped area anterior to Zone II, representing the remaining temporal retina.
  2. Severity (Stages): Describes the progressive ophthalmoscopic findings at the junction of vascularized and avascular retina.
     • Stage 1: A thin, flat, white demarcation line separating vascularized from avascular retina.
     • Stage 2: A raised, distinct ridge.
     • Stage 3: A ridge with extraretinal fibrovascular proliferation (neovascularization) extending from the retina into the vitreous.
     • Stage 4: Partial retinal detachment.
       • Stage 4A: Extrafoveal retinal detachment.
       • Stage 4B: Foveal retinal detachment.
     • Stage 5: Total retinal detachment (funnel-shaped).
  3. Presence of "Plus Disease": Indicates significant arteriolar tortuosity and venular dilation in the posterior pole, suggesting active, rapidly progressive ROP that is likely to lead to retinal detachment. Plus disease can be mild (pre-plus disease), moderate, or severe.
  4. "Aggressive Posterior ROP" (AP-ROP): A rare, severe, and rapidly progressive form of ROP characterized by posterior location (Zone I or posterior Zone II), prominent plus disease, and often flat neovascularization without distinct ridge formation. It progresses quickly to retinal detachment.

Pathophysiology

• Mechanism: ROP is a biphasic disease:
  • Phase 1 (Obliteration and Vasoconstriction): In premature infants, the immature retinal vessels are highly sensitive to oxygen tension. The relatively high ambient oxygen environment after birth, compared to the intrauterine hypoxic environment, leads to suppression of normal vascular endothelial growth factor (VEGF) production and subsequent arrest of normal retinal vascularization. This can lead to obliteration of existing immature vessels and a larger area of avascular peripheral retina. This phase typically occurs from birth to 32-34 weeks postmenstrual age (PMA).
  • Phase 2 (Pathologic Vasoproliferation): As the infant grows, the metabolic demands of the still-developing, avascular peripheral retina increase, leading to tissue hypoxia. This hypoxia triggers an upregulation of pro-angiogenic factors, most notably VEGF, leading to uncontrolled, abnormal neovascularization (Stage 3 ROP). These new vessels are fragile, prone to hemorrhage, and can cause fibrous tissue proliferation, leading to tractional retinal detachment (Stages 4 and 5). This phase typically occurs from 32-44 weeks PMA.
• Risk Factors:
  • Low Gestational Age (GA): Most significant risk factor. Infants born <30-32 weeks GA are at highest risk.
  • Low Birth Weight (BW): Most significant risk factor. Infants born <1500g are at highest risk; risk increases inversely with BW.
  • Oxygen Administration: Both excessive and fluctuating oxygen levels. While essential for survival, supplemental oxygen can suppress normal VEGF and lead to vasocobliteration in Phase 1. Subsequent removal or reduction can trigger Phase 2.
  • Infections/Sepsis: Sepsis, intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), patent ductus arteriosus (PDA), necrotizing enterocolitis (NEC).
  • Blood Transfusions: Repeated transfusions or large volumes of red blood cells.
  • Growth Restriction: Poor postnatal weight gain.
  • Racial/Ethnic Factors: White infants may have a slightly higher risk of severe ROP than Black infants.
  • Genetics: Emerging evidence suggests a genetic predisposition.
• Protective Factors:
  • Controlled Oxygen Supplementation: Maintaining oxygen saturation within target ranges (e.g., 89-94% or 90-95%) has shown some benefit in reducing severe ROP, though very tight control can increase mortality.
  • Human Milk Diet: May reduce risk of severe ROP due to various protective factors in breast milk.
  • Nutritional Support: Adequate caloric and protein intake to support healthy growth.
  • Caffeine Citrate: Used for apnea of prematurity, also shown to reduce ROP in some studies.
  • Early Administration of Intravenous Insulin: Small studies suggest a potential role in very low birth weight infants.

Clinical Presentation

Signs and Symptoms

ROP is typically asymptomatic in its early stages as the infant's vision cannot be assessed subjectively. Diagnosis relies solely on indirect ophthalmoscopy.

• Cardinal Features: Abnormal retinal vascular development observed on funduscopic examination. Progression from a demarcation line to a ridge with neovascularization, leading to vitreous hemorrhage and retinal detachment in severe cases.
• Early Signs (Stages 1-2):
  • Presence of an avascular peripheral retina.
  • A white demarcation line (Stage 1) separating vascularized from avascular retina.
  • A pink-white ridge (Stage 2), raised from the retinal surface.
  • Small clumps of developing vessels posterior to the ridge.
• Advanced Signs (Stages 3-5):
  • Stage 3: Ridge with extraretinal fibrovascular proliferation (neovascularization) extending from the ridge into the vitreous. This is the critical stage for intervention.
  • Plus Disease: Tortuosity and dilation of the posterior retinal arterioles and venules, often associated with iris engorgement, pupillary rigidity, and vitreous haze. Indicates high disease activity and rapid progression.
  • Stage 4A: Partial tractional retinal detachment, involving the peripheral retina but sparing the macula.
  • Stage 4B: Partial tractional retinal detachment involving the macula.
  • Stage 5: Total retinal detachment, often funnel-shaped, leading to blindness.
• Atypical Presentations:
  • Aggressive Posterior ROP (AP-ROP): Characterized by severe plus disease in Zone I or posterior Zone II, often with flat neovascularization rather than a classic ridge, and rapid progression to retinal detachment. It can be difficult to classify into distinct stages due to its fulminant nature.

Physical Examination

• Inspection: External ocular examination may reveal no abnormalities in early ROP. In advanced stages (Stage 5), leukocoria (a white pupil reflex due to the retinal detachment) or strabismus may be present. Iris engorgement and pupillary rigidity can be signs of plus disease.
• Palpation: Not applicable for direct diagnosis of ROP.
• Special Tests:
  • Indirect Ophthalmoscopy: The gold standard for diagnosing and monitoring ROP. Performed by an experienced ophthalmologist using an indirect ophthalmoscope and a specialized lens (e.g., 28D, 20D) to view the entire retina, including the ora serrata. This requires pupil dilation (e.g., phenylephrine 2.5% and cyclopentolate 0.5% or 1%, 1-2 drops applied 30-60 minutes prior to examination). Gentle scleral depression is often used to visualize the far periphery.
  • RetCam Imaging (Digital Retinal Photography): Digital images of the retina can be captured and reviewed by an ophthalmologist, particularly useful for telemedicine ROP screening programs. It allows for expert review from a distance and provides documentation for follow-up, but direct ophthalmoscopy remains the definitive diagnostic tool.

Diagnostic Approach

History Taking

• Key Questions:
  • Gestational Age (GA) at Birth: Essential for screening eligibility and risk assessment.
  • Birth Weight (BW): Essential for screening eligibility and risk assessment.
  • Postmenstrual Age (PMA) / Corrected Gestational Age: Crucial for timing of screening and follow-up examinations.
  • Oxygen Therapy History: Duration, peak concentrations, saturation targets.
  • Medical Comorbidities: History of sepsis, NEC, IVH, BPD, PDA, significant illness requiring prolonged ventilation or inotropes.
  • Transfusion History: Number and volume of red blood cell transfusions.
  • Medications: E.g., caffeine use.
• Red Flags:
  • Any infant meeting screening criteria who has not yet been examined by an ophthalmologist.
  • Rapid deterioration of systemic health in an infant with known ROP.
  • Signs of developing or worsening plus disease on examination.
  • Progression to Type 1 ROP indicating immediate need for treatment.

Laboratory Tests

• First-Line: No specific laboratory tests directly diagnose ROP. Diagnosis is purely clinical via ophthalmoscopy.
• Confirmatory: Not applicable.
• Monitoring: Not applicable for direct ROP monitoring, but monitoring of systemic factors (e.g., oxygen saturation, inflammatory markers) is part of overall neonatal care which indirectly impacts ROP risk and progression.

Imaging

• Recommended:
  • Indirect Ophthalmoscopy: (As described above) is the primary "imaging" technique for diagnosis and monitoring.
  • Digital Retinal Photography (e.g., RetCam): Increasingly used in screening programs for documentation, remote consultation (telemedicine ROP), and serial comparison. While not replacing direct ophthalmoscopy for initial diagnosis in all settings, it is highly recommended for documentation and supporting screening programs.
• Advanced:
  • Fluorescein Angiography (FA): Rarely used in ROP diagnosis due to its invasive nature and the need for general anesthesia in infants. It can be helpful in identifying areas of retinal non-perfusion or abnormal neovascularization not clearly visible on ophthalmoscopy, particularly in atypical or persistent cases, or to guide anti-VEGF retreatment.
  • Optical Coherence Tomography (OCT): Can provide cross-sectional images of the retina, useful in some cases to assess traction, macular involvement, or retinal detachment in later stages, but not a primary diagnostic tool for the initial stages of ROP.

Management

Management of ROP involves a combination of careful observation, timely intervention for progressive disease, and supportive care to minimize systemic risk factors.

Acute Management

• Immediate: Not typically an acute "emergency" in the sense of immediate, life-saving intervention upon initial diagnosis, unless presenting with very advanced stages (e.g., Stage 5 ROP with acute pain or signs of severe inflammation, though this is rare). The "acute" management phase focuses on timely screening and prompt treatment for sight-threatening ROP.
• Stabilization: Optimize the infant's systemic condition (e.g., maintaining stable oxygen saturation, managing sepsis, controlling blood pressure). While these do not directly treat ROP, they reduce progression risk and ensure the infant is stable enough for ophthalmic examination and potential treatment.
• Emergency: When Type 1 ROP is identified, treatment is considered an ophthalmic emergency due to the high risk of rapid progression to retinal detachment and irreversible vision loss if delayed. Treatment should be performed within 72 hours (or ideally 48 hours for Zone I disease).

Chronic Management

• Pharmacological:
  • Anti-VEGF Agents: (e.g., Bevacizumab, Ranibizumab, Aflibercept)
    • Mechanism: Inhibits vascular endothelial growth factor (VEGF), which is a key driver of pathological neovascularization in Phase 2 of ROP.
    • Indications: Used for Type 1 ROP, especially in Zone I ROP or AP-ROP. Studies like BEAT-ROP showed bevacizumab to be superior to laser for Zone I ROP and Zone II posterior ROP. It preserves the peripheral retina and is less painful than laser.
    • Dosages (intravitreal injection):
      • Bevacizumab (Avastin): 0.625 mg in 0.025 mL per eye (off-label use, commonly used).
      • Ranibizumab (Lucentis): 0.2 mg in 0.02 mL per eye (approved in some regions for ROP, generally less systemic absorption).
      • Aflibercept (Eylea): 0.4 mg in 0.01 mL per eye (also emerging use).
    • Adverse Effects: Potential for systemic absorption and effects on normal lung and brain development (though clinical studies have not shown significant long-term adverse effects compared to laser), endophthalmitis (rare), retinal detachment, cataract formation.
    • Monitoring: Requires close follow-up due to the potential for recurrence (late reactivation) as the drug effect wears off and VEGF levels rebound. Retreatment may be necessary.
• Non-pharmacological:
  • Laser Photocoagulation:
    • Mechanism: Ablation of the avascular peripheral retina, reducing the metabolic demand for oxygen and thereby reducing the stimulus for VEGF production.
    • Indications: Historically the gold standard, still widely used, especially for Zone II ROP. Effective for Type 1 ROP.
    • Procedure: Performed using a diode laser (often 810 nm wavelength) delivered through an indirect ophthalmoscope. Hundreds of laser spots are placed in the avascular retina, sparing the posterior vascularized retina.
    • Adverse Effects: Myopia, visual field restriction (due to retinal destruction), retinal detachment, choroidal hemorrhage, pain.
  • Cryotherapy: (Less common now, largely replaced by laser)
    • Mechanism: Freezing and destroying the avascular peripheral retina.
    • Indications: Historically used for threshold ROP, but largely superseded by laser due to less precision and more inflammation.
  • Scleral Buckle:
    • Mechanism: Places a silicone band around the sclera to indent the eye wall, relieving vitreous traction on the retina.
    • Indications: Used for Stage 4 ROP (retinal detachment).
  • Vitrectomy:
    • Mechanism: Surgical removal of vitreous hemorrhage and fibrovascular membranes, relieving traction on the retina.
    • Indications: Used for Stage 4B (macula-off detachment) and Stage 5 ROP (total retinal detachment). Prognosis for useful vision is poor in Stage 5.
• Monitoring:
  • Screening Examinations: Initial examination based on gestational age and birth weight (refer to specific guidelines, e.g., AAP, ASRS). Typically 4-6 weeks postnatal age or 31-32 weeks PMA, whichever is later.
  • Follow-up Examinations: Frequency depends on ROP severity and location (e.g., weekly for Zone I ROP, biweekly for Zone II, less frequently for milder disease or regressing ROP).
  • Post-Treatment Monitoring: Close follow-up is crucial after both laser and anti-VEGF.
    • Laser: Weekly until regression is evident, then every 1-2 weeks until full vascularization or confirmed regression.
    • Anti-VEGF: Often weekly or every 2 weeks initially, then extending to monthly, to monitor for recurrence and ensure continued vascularization. Follow-up can be prolonged for several months due to late recurrences.

Treatment Algorithms

The goal is to treat Type 1 ROP and avoid progression to retinal detachment. Type 2 ROP is observed. - First-Line: * Type 1 ROP Criteria (from Early Treatment for Retinopathy of Prematurity - ETROP study): 1. Zone I, Stage 3 ROP with plus disease (immediate treatment, within 48-72 hours) 2. Zone I, Stage 1 or 2 ROP with plus disease (immediate treatment, within 48-72 hours) 3. Zone II, Stage 2 or 3 ROP with plus disease (urgent treatment, within 72 hours) * Aggressive Posterior ROP (AP-ROP): Requires urgent treatment, regardless of specific staging. * Treatment Choice: * Zone I or AP-ROP: Anti-VEGF agents (e.g., bevacizumab) are increasingly preferred, as they are less destructive, allow continued peripheral retinal vascularization, and may be associated with better structural outcomes. * Zone II, posterior ROP (especially Stage 3 with plus disease): Both laser photocoagulation and anti-VEGF are effective options. Laser is definitive for the ablated area, while anti-VEGF requires prolonged follow-up due to potential for recurrence. The choice depends on clinician preference, patient characteristics, and available resources. - Second-Line: * If initial treatment (e.g., laser) fails to cause regression or ROP progresses, a second treatment (e.g., repeat laser, switch to anti-VEGF if not used initially, or surgical intervention) may be considered. - Refractory Cases: * Stage 4A ROP: Scleral buckle may be considered if traction is prominent. * Stage 4B or Stage 5 ROP: Surgical intervention (vitrectomy +/- scleral buckle) is indicated. Prognosis for useful vision is very poor for Stage 5 ROP.

Complications

• Common:
  • Myopia: High incidence, particularly after laser treatment due to scleral shortening and lens changes.
  • Strabismus: Misalignment of the eyes (e.g., esotropia, exotropia), often requiring surgical correction.
  • Amblyopia ("lazy eye"): Reduced vision in one or both eyes due to abnormal visual development. Common causes include strabismus, anisometropia (unequal refractive error), or media opacities. Requires patching or atropine therapy.
• Serious:
  • Retinal Detachment: The most severe complication, leading to significant vision loss or blindness. Can be tractional, rhegmatogenous, or exudative.
  • Vitreous Hemorrhage: Bleeding into the vitreous gel, obscuring vision and potentially leading to traction.
  • Glaucoma: Increased intraocular pressure, typically late-onset, requiring medical or surgical management.
  • Cataract: Opacification of the lens, sometimes as a complication of ROP surgery.
• Long-term:
  • Permanent vision impairment or blindness.
  • Need for lifelong ophthalmic follow-up for refractive errors, amblyopia, glaucoma, and late-onset retinal detachments.
  • Learning disabilities and developmental delays, though these are often related to prematurity itself rather than ROP specifically.

Prognosis

• Factors:
  • Stage of ROP at presentation: Earlier stages have better prognosis.
  • Presence of plus disease: Worsens prognosis significantly.
  • Zone of ROP: Zone I and posterior Zone II ROP have worse prognosis than Zone II anterior or Zone III ROP.
  • Timeliness and Effectiveness of Treatment: Prompt and successful treatment of Type 1 ROP significantly improves visual outcomes.
  • Development of Retinal Detachment: Stage 5 ROP has a very poor visual prognosis, even with surgery.
  • Associated Systemic Conditions: Severe comorbidities can indirectly impact outcomes.
• Survival: ROP itself is not a life-threatening condition, but it is a marker for severe prematurity, which carries a higher risk of mortality.
• Quality of Life: Children with severe ROP and significant vision loss may experience profound impact on their development, education, and overall quality of life, requiring extensive support. Visual outcomes vary widely. Many infants with mild ROP have excellent vision, while those with treated Type 1 ROP may have good functional vision but often with significant refractive errors (myopia) and other ocular sequelae.

Prevention

• Primary: Aimed at preventing the occurrence of ROP.
  • Preventing Prematurity: Most effective long-term strategy, though often challenging.
  • Controlled Oxygen Therapy: Maintaining oxygen saturation within a defined, narrow target range (e.g., 89-94% or 90-95%) and minimizing fluctuations. Avoid both hyperoxia and severe hypoxia.
  • Careful Management of Neonatal Comorbidities: Aggressive management of sepsis, PDA, BPD, and other conditions that increase metabolic demand or systemic inflammation.
  • Nutritional Optimization: Ensuring adequate nutrition to promote healthy growth, especially during the period of retinal vascular development.
  • Caffeine Citrate: For apnea of prematurity, also shown to reduce ROP incidence and severity in some trials (e.g., CAP trial).
  • Human Milk Fortification: Encouraging human milk feeding.
• Secondary: Early detection and intervention to prevent severe ROP and its complications.
  • Adherence to Screening Guidelines: Regular and timely ophthalmic examinations by experienced ophthalmologists for all at-risk infants.
    • AAP/AAO/ASRS Guidelines: Infants with birth weight ≤1500g or gestational age ≤30 weeks, or infants with birth weight 1500-2000g or gestational age >30 weeks with an unstable clinical course.
    • Timing of First Examination: Usually 4-6 weeks after birth, or by 31-32 weeks postmenstrual age (PMA), whichever is later. For very premature infants (<24-25 weeks GA), the initial exam might be delayed to 30-31 weeks PMA.
  • Prompt Treatment of Type 1 ROP: Expedited referral and treatment as soon as Type 1 ROP is diagnosed.
• Tertiary: Preventing further complications and maximizing visual function in those with ROP.
  • Long-term Ophthalmic Follow-up: Regular check-ups for refractive errors, amblyopia, strabismus, glaucoma, and late retinal detachments in all children with a history of ROP, especially those who received treatment.
  • Amblyopia Management: Prompt treatment of amblyopia with patching or atropine.
  • Low Vision Services: Referral to low vision specialists and support services for children with significant visual impairment.

Special Populations

• Pediatric: ROP is exclusively a disease of preterm infants and neonates. All sections above directly pertain to this population. Emphasis is placed on atraumatic examination, proper pain management during examinations and procedures, and appropriate sedation if necessary. Long-term follow-up into childhood is critical.
• Geriatric: Not applicable.
• Pregnancy: Not applicable.
• Comorbidities:
  • Bronchopulmonary Dysplasia (BPD): Infants with severe BPD often require prolonged oxygen support, which is a risk factor for ROP. Careful oxygen titration is paramount.
  • Intraventricular Hemorrhage (IVH): Severe IVH can be associated with increased ROP risk due to systemic instability.
  • Sepsis/Necrotizing Enterocolitis (NEC): Systemic inflammation associated with these conditions can increase ROP severity. Aggressive management is important.
  • Patent Ductus Arteriosus (PDA): Hemodynamically significant PDA can alter systemic blood flow and retinal perfusion, potentially influencing ROP.
  • Poor Postnatal Growth: Growth restriction after birth is an independent risk factor for ROP. Aggressive nutritional support is important.

Clinical Pearls

• Diagnostic:
  • Timing is critical: Adhere strictly to ROP screening guidelines based on gestational age and birth weight to avoid missing treatable ROP.
  • Know the Zones and Stages: Precise localization and staging are crucial for management decisions (e.g., Zone I vs. Zone II).
  • "Plus Disease" is the game-changer: Always look for plus disease as it indicates high activity and urgent need for intervention, even in earlier stages.
  • Periphery matters: Scleral depression is essential to visualize the far peripheral retina, where most ROP initiates.
  • Telemedicine is a valuable adjunct: RetCam imaging can enhance documentation and facilitate expert consultation, but doesn't fully replace direct ophthalmoscopy.
• Treatment:
  • Timely intervention: Type 1 ROP is an emergency; treatment should not be delayed.
  • Anti-VEGF vs. Laser: Both are effective. Anti-VEGF may be preferred for Zone I/AP-ROP due to preserving peripheral vision, but requires longer follow-up for potential recurrence. Laser is often simpler for Zone II disease but causes permanent peripheral field loss.
  • Pain management: Ensure adequate analgesia for the infant during laser treatment.
  • Long-term follow-up: Emphasize to parents the need for lifelong eye care, even after successful ROP treatment, due to high rates of myopia, strabismus, amblyopia, and late retinal complications.
• Pitfalls:
  • Missing the first exam: Crucial for early detection.
  • Inadequate dilation: Leads to incomplete examination and missed pathology.
  • Inexperience: ROP diagnosis and management require significant experience in indirect ophthalmoscopy and neonatal care. Referral to a specialized ROP center is advisable if local expertise is lacking.
  • Over-oxygenation or under-oxygenation: Both can exacerbate ROP. Maintain strict oxygen saturation targets.
  • Underestimation of AP-ROP: This form progresses extremely rapidly and requires immediate, aggressive management.
  • Forgetting about late recurrence: Especially after anti-VEGF therapy, ROP can reactivate months after initial treatment. Prolonged follow-up is essential.

Recent Updates

• Guidelines:
  • Updated ICROP (ICROP3, 2021): Provides more detailed descriptions of specific ROP features, including aggressive ROP, peripheral vascular abnormalities, and posterior pole characteristics. It aims to standardize classification for research and clinical practice.
  • AAP/AAO/ASRS Screening Guidelines (most recent updates): Continuously refined to optimize screening criteria and timing, often incorporating new evidence on risk factors and presentation patterns.
• Evidence:
  • Growing evidence for Anti-VEGF agents: While laser remains effective, anti-VEGF therapy (particularly bevacizumab and ranibizumab) has emerged as a strong alternative, especially for Zone I and aggressive posterior ROP, due to better structural outcomes and preservation of peripheral vision. However, concerns about systemic absorption and long-term neurodevelopmental effects are still being studied.
  • Telemedicine ROP Screening: Digital imaging platforms (e.g., RetCam) combined with remote expert review have proven effective and safe for ROP screening, increasing access to care, especially in underserved areas.
  • Randomized Controlled Trials: Ongoing research continues to refine optimal oxygen saturation targets, explore novel systemic interventions, and compare long-term outcomes of different treatment modalities (laser vs. anti-VEGF).
• Controversies:
  • Optimal oxygen saturation targets: While narrow ranges are accepted, precise upper and lower limits are still debated, balancing ROP risk with other neonatal morbidities (e.g., mortality, NEC).
  • Long-term systemic safety of anti-VEGF agents: Concerns persist regarding the potential impact of systemic anti-VEGF exposure on organ development, particularly in the brain and lungs, although current data are reassuring.
  • Cost-effectiveness and long-term recurrence rates of anti-VEGF vs. laser: Balancing the benefits of anti-VEGF with the need for prolonged follow-up and the potential for late recurrence remains a clinical challenge.

Key References

• Guidelines:
  • American Academy of Pediatrics (AAP), American Academy of Ophthalmology (AAO), American Association for Pediatric Ophthalmology and Strabismus (AAPOS), American Society of Retina Specialists (ASRS) Joint Statement on ROP Screening: Current recommendations for screening and management. (e.g., latest version is Screening Examination of Premature Infants for Retinopathy of Prematurity, American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, and American Society of Retina Specialists. Pediatrics. 2018;142(6):e20183061)
  • International Classification of Retinopathy of Prematurity (ICROP) revisited: an update on the international classification of retinopathy of prematurity. (ICROP3: International Classification of Retinopathy of Prematurity Revised 2005. Archives of Ophthalmology. 2005;123(7):991-999. Updated: The International Classification of Retinopathy of Prematurity Revisited. JAMA Ophthalmol. 2021;139(7):793-799.)
• Studies:
  • Early Treatment for Retinopathy of Prematurity (ETROP) Study: Landmark multicenter randomized trial establishing criteria for early treatment of high-risk ROP. (Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity from the Early Treatment for Retinopathy of Prematurity Study. Arch Ophthalmol. 2003;121(12):1684-1694.)
  • Bevacizumab for Retinopathy of Prematurity (BEAT-ROP) Trial: Compared bevacizumab with laser photocoagulation for Zone I or posterior Zone II ROP. (Mintz-Hittner HA, Kennedy KA, Chuang VP. Efficacy of intravitreal bevacizumab for retinopathy of prematurity. N Engl J Med. 2011;364(7):603-615.)
  • STOP-ROP Study: Examined the role of supplemental oxygen in preventing ROP. (Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP) Trial. Arch Ophthalmol. 2000;118(6):751-759.)
  • BOOST II Trials: Investigated the optimal oxygen saturation target ranges for preterm infants. (Oxygen saturation and the development of retinopathy of prematurity. N Engl J Med. 2013;368(19):1844-1845.)
• Reviews:
  • Numerous comprehensive reviews on ROP pathophysiology, screening, and treatment are available in major ophthalmology and neonatology journals (e.g., Ophthalmology, Journal of Pediatrics, Neonatology).
  • Cochrane Reviews on specific interventions (e.g., anti-VEGF, laser, oxygen targets).